JP2019505564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505564A5 JP2019505564A5 JP2018544769A JP2018544769A JP2019505564A5 JP 2019505564 A5 JP2019505564 A5 JP 2019505564A5 JP 2018544769 A JP2018544769 A JP 2018544769A JP 2018544769 A JP2018544769 A JP 2018544769A JP 2019505564 A5 JP2019505564 A5 JP 2019505564A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acid
- host cell
- binding moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255255P | 2015-11-13 | 2015-11-13 | |
| US62/255,255 | 2015-11-13 | ||
| US201562257493P | 2015-11-19 | 2015-11-19 | |
| US62/257,493 | 2015-11-19 | ||
| PCT/US2016/061320 WO2017083511A1 (en) | 2015-11-13 | 2016-11-10 | Anti-bcma polypeptides and proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505564A JP2019505564A (ja) | 2019-02-28 |
| JP2019505564A5 true JP2019505564A5 (enExample) | 2019-12-19 |
| JP6901493B2 JP6901493B2 (ja) | 2021-07-14 |
Family
ID=57354453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544769A Active JP6901493B2 (ja) | 2015-11-13 | 2016-11-10 | 抗ｂｃｍａポリペプチド及びタンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10925969B2 (enExample) |
| EP (1) | EP3374396A1 (enExample) |
| JP (1) | JP6901493B2 (enExample) |
| KR (1) | KR102776145B1 (enExample) |
| CN (1) | CN108473575B (enExample) |
| AU (1) | AU2016353067B2 (enExample) |
| CA (1) | CA3005042A1 (enExample) |
| WO (1) | WO2017083511A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201990959A1 (ru) * | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| PH12017501834B1 (en) | 2015-04-06 | 2024-01-17 | Arcellx Inc | De novo binding domain containing polypeptides and uses thereof |
| US20190194338A1 (en) | 2016-02-17 | 2019-06-27 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
| IL270415B2 (en) | 2017-05-12 | 2024-08-01 | Crispr Therapeutics Ag | Materials and methods for cell engineering and their uses in immuno-oncology |
| US11166985B2 (en) * | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| CN111511383A (zh) | 2017-11-14 | 2020-08-07 | 阿奇利克斯股份有限公司 | 多功能免疫细胞疗法 |
| MX2020004933A (es) | 2017-11-14 | 2021-01-08 | Arcellx Inc | Polipéptidos que contienen dominios d y sus usos. |
| JP7438953B2 (ja) * | 2018-02-01 | 2024-02-27 | イノベント バイオロジックス （スウツォウ） カンパニー，リミテッド | 完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用 |
| US11401336B2 (en) * | 2018-02-21 | 2022-08-02 | Celgene Corporation | BCMA-binding antibodies and uses thereof |
| WO2019215500A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| WO2020004934A1 (ko) * | 2018-06-26 | 2020-01-02 | 에이비엘바이오 주식회사 | 항-bcma 항체 및 그 용도 |
| EA202190315A1 (ru) | 2018-07-19 | 2021-04-16 | Ридженерон Фармасьютикалз, Инк. | Химерные антигенные рецепторы со специфичностью к bcma и их применение |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| BR112021005669A2 (pt) * | 2018-09-28 | 2021-06-22 | Amgen Inc. | anticorpos contra bcma solúvel |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| US20210246220A1 (en) * | 2018-10-10 | 2021-08-12 | Bgi Shenzhen | Anti-BCMA single-chain antibody scFv and preparation method and application thereof |
| CA3116413A1 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| US12540190B2 (en) * | 2019-07-30 | 2026-02-03 | Shanghai Hansoh Biomedical Co., Ltd. | Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof |
| CN112409482B (zh) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | Bcma抗体 |
| WO2021190564A1 (zh) * | 2020-03-26 | 2021-09-30 | 上海翰森生物医药科技有限公司 | 抗体药物偶联物及其医药用途 |
| KR20250047766A (ko) | 2022-08-05 | 2025-04-04 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d 및 bcma에 특이적인 키메라 항원 수용체 |
| WO2024051796A1 (en) * | 2022-09-09 | 2024-03-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Albumin binding proteins, fusion proteins and uses thereof |
| CN117164714B (zh) * | 2023-10-08 | 2024-04-23 | 北京奇迈永华生物科技有限公司 | 一种靶向bcma的抗体及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892827A (en) | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| JP2665827B2 (ja) | 1990-05-11 | 1997-10-22 | アメリカ合衆国 | 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素 |
| US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
| EP0646175B1 (en) | 1992-06-18 | 2005-12-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Recombinant pseudomonas exotoxin with increased activity |
| UA74798C2 (uk) * | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| RU2464276C2 (ru) | 2005-05-18 | 2012-10-20 | Аблинкс Н.В. | Улучшенные нанотела против фактора некроза опухоли-альфа |
| EP3006456B1 (en) | 2005-07-29 | 2018-09-19 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Mutated pseudomonas exotoxins with reduced antigenicity |
| CA2698357C (en) | 2007-09-04 | 2017-06-06 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| AU2010224160A1 (en) * | 2009-03-10 | 2011-09-22 | Biogen Idec Ma Inc. | Anti-BCMA antibodies |
| EP2475398B1 (en) | 2009-09-11 | 2015-05-20 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Improved pseudomonas exotoxin a with reduced immunogenicity |
| WO2011047121A1 (en) * | 2009-10-14 | 2011-04-21 | Schering Corporation | April antagonists and methods of use |
| SG194176A1 (en) * | 2011-05-27 | 2013-12-30 | Glaxo Group Ltd | Bcma (cd269/tnfrsf17) -binding proteins |
| EP3231812B1 (en) | 2011-06-09 | 2020-03-25 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes |
| PL2755993T3 (pl) | 2011-09-16 | 2018-04-30 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Egzotoksyna A Pseudomonas z mniej immunogennymi epitopami komórek B |
| EA201990959A1 (ru) * | 2012-04-11 | 2020-02-10 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| EP2914628A1 (en) | 2012-11-01 | 2015-09-09 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| JP6584012B2 (ja) | 2013-10-06 | 2019-10-02 | アメリカ合衆国 | 改変シュードモナス外毒素ａ |
| US10174095B2 (en) * | 2014-07-21 | 2019-01-08 | Novartis Ag | Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor |
-
2016
- 2016-11-10 AU AU2016353067A patent/AU2016353067B2/en active Active
- 2016-11-10 CN CN201680065438.5A patent/CN108473575B/zh active Active
- 2016-11-10 EP EP16798612.4A patent/EP3374396A1/en not_active Ceased
- 2016-11-10 WO PCT/US2016/061320 patent/WO2017083511A1/en not_active Ceased
- 2016-11-10 JP JP2018544769A patent/JP6901493B2/ja active Active
- 2016-11-10 US US15/773,687 patent/US10925969B2/en active Active
- 2016-11-10 KR KR1020187016668A patent/KR102776145B1/ko active Active
- 2016-11-10 CA CA3005042A patent/CA3005042A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505564A5 (enExample) | ||
| CN113423735B (zh) | 抗-紧密连接蛋白抗体及其用途 | |
| JP2016500655A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2015510761A5 (enExample) | ||
| JP2017531427A5 (enExample) | ||
| JP2010511388A5 (enExample) | ||
| JP2013506428A5 (enExample) | ||
| JP2011505875A5 (enExample) | ||
| JP2016138129A5 (enExample) | ||
| JP2010510809A5 (enExample) | ||
| JP2015526387A5 (enExample) | ||
| Stone et al. | The assembly of single domain antibodies into bispecific decavalent molecules | |
| JP2012523848A5 (enExample) | ||
| JP2017526339A5 (enExample) | ||
| JP2016533721A5 (enExample) | ||
| JP2003523771A5 (enExample) | ||
| JP2010533498A5 (enExample) | ||
| JP2016536342A5 (enExample) | ||
| JP2020533004A5 (enExample) | ||
| JP2013519364A5 (enExample) | ||
| JP2019512207A5 (enExample) | ||
| CN110831973A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2018530331A5 (enExample) | ||
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 |